News Column

BioSyent Named to the 2013 TSX Venture Top 50(R) Ranking-2nd Consecutive Year Chosen as a Top TSX Performer

Feb 14 2013 12:00AM



TORONTO, ONTARIO -- (Marketwire) -- 02/14/13 -- BioSyent Inc. ("BioSyent") (TSX VENTURE: RX) announced today that it has been named as one of the TSX Venture Top 50 companies.

The 2013 TSX Venture 50 is an annual ranking of strong performing emerging companies listed on the TSX Venture Exchange. The TSX Venture 50 includes the top 10 companies in five major industry sectors that have been identified as leaders in Canada's public venture market. BioSyent is ranked seventh in the list of ten leading Technology and Life Sciences companies for the year. Companies are selected based on four equally weighted criteria - return on investment, trading activity, market capitalization growth, and analyst coverage. The results were obtained from data to December 31, 2012.

"With more than 2,200 companies listed on the TSX Venture Exchange, it is an honour to have BioSyent named for two consecutive years as one of the TSX Venture Top 50 companies," said Rene Goehrum, President and CEO of BioSyent Inc. "Our business has progressed considerably since we were named to the 2012 TSX Venture 50. Being named to the 2013 TSX Venture 50 is further investor validation of our business model and results."

BioSyent Inc. continues to concentrate on its pharmaceutical strategy to source products that have been successfully developed and proven to be safe and effective; manage these products through the regulatory process and product registration (approval); and once approved, market these products in Canada. The Company is focused on medications, which occupy a niche in the market, are unique either due to complexity of manufacture or provide novel technological or therapeutic advantages, or that are backed by strong partners holding intellectual property rights that are defendable. This strategy allows the Company to market these medications as brands owned by, or licensed to, it.

BioSyent Inc. is a publicly traded specialty pharmaceutical company whose wholly owned subsidiary, BioSyent Pharma Inc., sources, acquires or in-licences pharmaceutical products and markets these products in Canada. Wholly owned BioSyent subsidiary Hedley Technologies Ltd. operates the company's legacy business marketing bio and health friendly non-chemical insecticides. BioSyent common shares are listed for trading on the TSX Venture Exchange (TSXV) under the symbol RX.

BioSyent Inc.
Rene C. Goehrum
President and CEO

Source: Marketwire

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters